Skip to main content

James Crowe

The Front Lines: Vanderbilt physicians, researchers join worldwide fight against COVID-19

May. 14, 2020—From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic.

Read more


Antibodies eye Pacific Island “fever”

May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

Read more


Antibody finding raises hopes for Marburg, COVID-19 treatments

Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection.

Read more


Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Apr. 9, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Read more


Researchers developing potential coronavirus antibody therapies

Apr. 8, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Read more


VUMC-led team isolates antibody that blocks bird flu

Dec. 12, 2019—VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.

Read more


Flu’s “hidden target” may lead to universal vaccine: study

May. 16, 2019—The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much.

Read more


VUMC chikungunya antibody set to enter clinical trial

Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

Read more


Researchers push forward frontiers of vaccine science

Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.

Read more


Designing antibodies to fight the flu

Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.

Read more


VUMC scientists ‘sprint’ to find anti-Zika antibodies

Jan. 25, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

Read more


Research explores link between stem cell transplant, diabetes

Jan. 17, 2019—Brian Engelhardt is studying why as many as 50 percent of stem cell transplant recipients develop diabetes.

Read more


VIEW MORE EVENTS >